ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!BTAI Company Profile and Key Details
BioXcel Therapeutics, Inc.
BTAI Stock Price Chart
Stock Price Today
BioXcel Therapeutics, Inc. (BTAI) stock surged +73.61%, trading at $3.75 on NASDAQ, up from the previous close of $2.16. The stock opened at $2.37, fluctuating between $2.37 and $6.81 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Company Information
| Employees | 74 |
| Beta | -0.01 |
| Sales or Revenue | $1.38M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) stock price is $3.75 in the last trading session. During the trading session, BTAI stock reached the peak price of $6.81 while $2.37 was the lowest point it dropped to. The percentage change in BTAI stock occurred in the recent session was 73.61% while the dollar amount for the price change in BTAI stock was $1.59.
The NASDAQ listed BTAI is part of Biotechnology industry that operates in the broader Healthcare sector. BioXcel Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Robert Risinger M.D.
Chief Medical Officer - Neuroscience
Dr. Krishnan Nandabalan Ph.D.
Chief Digital Officer ?& Director
Dr. Vincent J. O'Neill B.Sc., M.D., M.R.C.P.
Senior Vice President and Chief R&D Officer of OnkosXcel Therapeutics
Dr. Cedric Burg
Vice President and Head of Global Clinical Operations & Project Management
Dr. Iris Francesconi Ph.D.
Chief Strategy Officer & Head of Investor Relations
Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P.
Senior Vice President & Chief Medical Officer
Dr. Frank D. Yocca Ph.D.
Senior Vice President & Chief Scientific Officer
Mr. Javier Rodriguez
Senior Vice President, Chief Legal Officer & Corporation Sec.
Mr. Richard I. Steinhart MBA
Senior Vice President & Chief Financial Officer
Dr. Chetan D. Lathia Ph.D.
Senior Vice President and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs
Dr. Vimal D. Mehta Ph.D.
Founder, Chief Executive Officer, Pres, & Director
Dr. Friso Postma
Senior Director of Neuroscience & Artificial intelligence
Mr. Matthew Wiley
Senior Vice President & Chief Commercial Officer
Mr. Robert Scala
Vice President of Commercial Operations & Launch Planning
BTAI's closing price is 118.02% higher than its 52-week low of $1.72 where as its distance from 52-week high of $52.80 is -92.9%.
Number of BTAI employees currently stands at 74.
Official Website of BTAI is: https://www.bioxceltherapeutics.com
BTAI could be contacted at phone 475 238 6837 and can also be accessed through its website. BTAI operates from 555 Long Wharf Drive, New Haven, CT 06511, United States.
BTAI stock volume for the day was 146.57M shares. The average number of BTAI shares traded daily for last 3 months was 1.95M.
The market value of BTAI currently stands at $11.63M with its latest stock price at $3.75 and 3.1M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com